Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: SARS-CoV-2
Interventions: Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose; Drug · Biological
Lead sponsor: Sean Liu; Other
Eligibility: 18 Years to 59 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab, LymphDetect assay, Surgery +/- neoadjuvant pembrolizumab; Drug · Radiation · Diagnostic Test + 1 more
Lead sponsor: Kevin Contrera; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Risk of Premature Ovarian Failure, Fertility Preservation
Interventions: surgery to remove ovaries or high dose chemotherapy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma
Interventions: TIL, Interleukin-2, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 39 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions: mHSCT, cyclophosphamide; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more

Conditions: Hypertension in Pregnancy
Interventions: Labetalol or Nifedipine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 89 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Keratoconjunctivitis Sicca
Interventions: Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution; Drug
Lead sponsor: Mitotech, SA; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 216
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more

Conditions: Chronic Kidney Diseases, Obesity
Interventions: SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide; Behavioral · Drug
Lead sponsor: Srinvasan Beddhu; Other
Eligibility: 20 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Stanford, California • Salt Lake City, Utah

Conditions: Idiopathic Short Stature
Interventions: Vosoritide Injection, Human Growth Hormone, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 35
States / cities: California City, California • Los Angeles, California • Oakland, California + 28 more

Conditions: Acute-graft-versus-host Disease
Interventions: AAT, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more

Conditions: Multiple Myeloma
Interventions: Melphalan, Velcade, Thalidomide, Dexamethasone; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Kidney Transplantation
Interventions: bleselumab, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 16 more

Conditions: Sleep Apnea, Obstructive, Obesity
Interventions: Propofol Alone, Propofol+Benzo/Opioids; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neoplasm Metastasis
Interventions: Olaratumab, Doxorubicin, Vincristine, Irinotecan, Ifosfamide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Up to 17 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more

Conditions: HIV Infections
Interventions: Enfuvirtide, Raltegravir, Darunavir, Tipranavir, Etravirine, Maraviroc; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 61
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 34 more

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Interventions: ASTX727; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more

Conditions: Leukemia
Interventions: Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 103
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more

Conditions: Neoplasms
Interventions: BXQ-350; Drug
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Lexington, Kentucky • Albuquerque, New Mexico • Cincinnati, Ohio + 1 more

Conditions: Hyperthermia
Interventions: This protocol will utilize a sauna as the primary method of detoxification.; Other
Lead sponsor: Bastyr University; Other
Eligibility: 21 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
Interventions: Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin; Device · Drug
Lead sponsor: AeRang Kim; Other
Eligibility: Up to 30 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Coronary Artery Disease (CAD), Ischemic Heart Disease
Interventions: Flurpiridaz (18F) Injection; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 5
States / cities: Hialeah, Florida • Miami, Florida • North Miami Beach, Florida + 2 more

Conditions: Human Immunodeficiency Virus
Interventions: Placebo, Pembrolizumab; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neurotrophic Keratopathy
Interventions: MR-146; Genetic
Lead sponsor: Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Sun City, Arizona • Tucson, Arizona • Glendale, California + 8 more

Search by objective public record fields.

A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

Cryopreservation of Ovarian Tissue

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Scleroderma: Cyclophosphamide or Transplantation

Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Sit Less, Interact and Move More (SLIMM) 2 Study

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

Propofol vs Propofol + Benzo/Opiates in High Risk Group

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

Sauna Detoxification Study: Pilot Feasibility

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

A Single Dose of Pembrolizumab in HIV-Infected People

A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy